IP Library Granted Patent US 12,383,746
Granted Patent B2
US 12,383,746 · App. 18/464,189 · Granted Aug 12, 2025

Synchronization of anti-tachycardia pacing in an extra-cardiovascular implantable system

Inventor: Troy E. Jackson (Rogers, MN)
Assignee: Medtronic, Inc.
A61N1/3621A61B5/363A61B5/4836A61N1/36514A61N1/3956A61N1/3962A61N1/3987A61N1/0504A61N1/0563A61N1/3622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,746
App. No.
18/464,189
Filed
Sep 8, 2023
Granted
Aug 12, 2025
Kind
B2
Art Unit
3792
USPC
607/14
Abstract

An extra-cardiovascular implantable cardioverter defibrillator (ICD) system receives a cardiac electrical signal by an electrical sensing circuit via an extra-cardiovascular sensing electrode vector and senses cardiac events from the cardiac electrical signal. The ICD system detects tachycardia from the cardiac electrical signal and determines a tachycardia cycle length from the cardiac electrical signal. The ICD system determines an ATP interval based on the tachycardia cycle length and sets an extended ATP interval that is longer than the ATP interval. The ICD delivers ATP pulses to a patient's heart via an extra-cardiovascular pacing electrode vector different than the sensing electrode vector. The ATP pulses include a leading ATP pulse delivered at the extended ATP interval after a cardiac event is sensed from the cardiac electrical signal and a second ATP pulse delivered at the ATP interval following the leading ATP pulse.

Claims (82)

1. A medical device comprising:

a sensing circuit configured to:

receive a first cardiac electrical signal via a first electrode pair;

sense cardiac events each associated with a myocardial depolarization from the first cardiac electrical signal;

receive a second cardiac electrical signal via a second electrode pair different than the first electrode pair;

a control circuit configured to:

determine a difference time interval between a cardiac event sensed from the first cardiac electrical signal and a fiducial point of the second cardiac electrical signal;

detect tachycardia from the first cardiac electrical signal; and

determine a first anti-tachycardia pacing (ATP) interval based on at least the difference time interval; and

a therapy delivery circuit configured to, in response to the control circuit detecting the tachycardia, deliver an ATP therapy by delivering a first leading ATP pulse at the first ATP interval from a cardiac event sensed by the sensing circuit from the first cardiac electrical signal after the control circuit detects the tachycardia.

2. The medical device of claim 1 wherein the control circuit is further configured to:

determine a tachycardia cycle length from the first cardiac electrical signal; and

determine the first ATP interval based on the tachycardia cycle length and the difference time interval.

3. The medical device of claim 1 wherein:

the control circuit is further configured to:

determine a tachycardia cycle length from the first cardiac electrical signal; and

determine a second ATP interval based on the determined tachycardia cycle length; and

the therapy delivery circuit is further configured to deliver the ATP therapy by delivering a second ATP pulse at the second ATP interval from the first leading ATP pulse.

4. The medical device of claim 3 wherein the control circuit is further configured to:

determine the first ATP interval based on a first percentage of the tachycardia cycle length and the difference time interval; and

determine the second ATP interval based on a second percentage of the tachycardia cycle length.

5. The medical device of claim 1 further comprising a memory, wherein:

the control circuit is further configured to:

determine from the second cardiac electrical signal an actual leading time interval to the first leading ATP pulse; and

store the actual leading time interval in the memory.

6. The medical device of claim 1 further comprising a memory, wherein:

the control circuit is further configured to:

determine a tachycardia cycle length from the first cardiac electrical signal;

determine an actual prematurity of the first leading ATP pulse based on at least the tachycardia cycle length and the first ATP interval;

determine a first total prematurity of the ATP therapy including the actual prematurity of the first leading pulse; and

store the first total prematurity in the memory.

7. The medical device of claim 6 wherein:

the control circuit is further configured to redetect the tachycardia after the therapy delivery circuit delivers the ATP therapy; and

the therapy delivery circuit is further configured to deliver the ATP therapy having a second total prematurity that is greater than the first total prematurity of the ATP therapy after the control circuit redetects the tachycardia.

8. The medical device of claim 1 wherein the therapy delivery circuit is further configured to deliver the ATP therapy via the second electrode pair.

9. The medical device of claim 1 wherein the therapy delivery circuit is further configured to deliver the ATP therapy via a third electrode pair, the third electrode pair having a common electrode with the second electrode pair.

10. The medical device of claim 1 wherein the control circuit is further configured to determine the fiducial point of the second cardiac electrical signal by determining at least one of:

a threshold crossing;

a maximum slope; or

a maximum peak.

11. A method comprising:

receiving a first cardiac electrical signal via a first electrode pair;

sensing cardiac events each associated with a myocardial depolarization from the first cardiac electrical signal;

receiving a second cardiac electrical signal via a second electrode pair different than the first electrode pair;

determining a difference time interval between a cardiac event sensed from the first cardiac electrical signal and a fiducial point of the second cardiac electrical signal;

detecting tachycardia from the first cardiac electrical signal;

determining a first anti-tachycardia pacing (ATP) interval based on at least the difference time interval; and

in response to detecting the tachycardia, delivering an ATP therapy by delivering a first leading ATP pulse at the first ATP interval from a cardiac event sensed by the sensing circuit from the first cardiac electrical signal after detecting the tachycardia.

12. The method of claim 11 further comprising:

determining a tachycardia cycle length from the first cardiac electrical signal; and

determining the first ATP interval based on the tachycardia cycle length and the difference time interval.

13. The method of claim 11 further comprising:

determining a tachycardia cycle length from the first cardiac electrical signal; and

determining a second ATP interval based on the determined tachycardia cycle length; and

the therapy delivery circuit is further configured to deliver the ATP therapy by delivering a second ATP pulse at the second ATP interval from the first leading ATP pulse.

14. The method of claim 13 further comprising:

determining the first ATP interval based on a first percentage of the tachycardia cycle length and the difference time interval; and

determining the second ATP interval based on a second percentage of the tachycardia cycle length.

15. The method of claim 11 further comprising:

determining from the second cardiac electrical signal an actual leading time interval to the first leading ATP pulse; and

storing the actual leading time interval in a memory of a medical device.

16. The method of claim 11 further comprising:

determining a tachycardia cycle length from the first cardiac electrical signal;

determining an actual prematurity of the first leading ATP pulse based on at least the tachycardia cycle length and the first ATP interval; and

determining a first total prematurity of the ATP therapy including the actual prematurity of the first leading pulse.

17. The method of claim 16 further comprising:

redetecting the tachycardia after the ATP therapy is delivered; and

after redetecting the tachycardia, delivering the ATP therapy having a second total prematurity that is greater than the first total prematurity.

18. The method of claim 11 further comprising delivering the ATP therapy via the second electrode pair.

19. The method of claim 11 further comprising delivering the ATP therapy via a third electrode pair, the third electrode pair having a common electrode with the second electrode pair.

20. The method of claim 11 further comprising determining the fiducial point of the second cardiac electrical signal by determining at least one of:

a threshold crossing;

a maximum slope; or

a maximum peak.

21. A non-transitory computer readable medium storing a set of instructions which, when executed by a control circuit of a medical device, cause the medical device to:

receive a first cardiac electrical signal via a first electrode pair;

sense cardiac events each associated with a myocardial depolarization from the first cardiac electrical signal;

receive a second cardiac electrical signal via a second electrode pair different than the first electrode pair;

determine a difference time interval between a cardiac event sensed from the first cardiac electrical signal and a fiducial point of the second cardiac electrical signal;

detect tachycardia from the first cardiac electrical signal;

determine an anti-tachycardia pacing (ATP) interval based on at least the difference time interval; and

in response to detecting the tachycardia, delivering an ATP therapy by delivering a first leading ATP pulse of the ATP therapy at the ATP interval from a cardiac event sensed by the sensing circuit from the first cardiac electrical signal after detecting the tachycardia.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2023
From: JACKSON, TROY E.
To: MEDTRONIC, INC.
Reel/Frame 065725/0827 →
Continuity (3)
Continuation 17323008 · May 18, 2021
Continuation 15071231 · Mar 16, 2016
Related Publication 20240042212A1 · Feb 8, 2024
References Cited (68)
US 4967746A · Vandegriff · 1990 [cited by applicant]
US 5181511A · Nickolls et al. · 1993 [cited by applicant]
US 5331966A · Bennett et al. · 1994 [cited by applicant]
US 5339820A · Henry et al. · 1994 [cited by applicant]
US 5458619A · Olson · 1995 [cited by applicant]
US 5545186A · Olson et al. · 1996 [cited by applicant]
US 5755739A · Sun · 1998 [cited by applicant]
US 6167308A · DeGroot · 2000 [cited by applicant]
US 6654639B1 · Lu · 2003 [cited by applicant]
US 6885890B2 · Spinelli et al. · 2005 [cited by applicant]
US 6952610B2 · Ostroff et al. · 2005 [cited by applicant]
US 7146214B2 · Struble · 2006 [cited by applicant]
US 7260433B1 · Falkenberg et al. · 2007 [cited by applicant]
US 7277755B1 · Falkenberg et al. · 2007 [cited by applicant]
US 7383091B1 · Chitre · 2008 [cited by applicant]
US 7386342B1 · Falkenberg et al. · 2008 [cited by applicant]
US 7502645B2 · Ostroff et al. · 2009 [cited by applicant]
US 7567835B2 · Gunderson · 2009 [cited by applicant]
US 7684862B2 · Belk et al. · 2010 [cited by applicant]
US 7761150B2 · Ghanem et al. · 2010 [cited by applicant]
US 7761153B2 · Belk et al. · 2010 [cited by applicant]
US 7761155B2 · Belk et al. · 2010 [cited by applicant]
US 7792578B2 · Belk et al. · 2010 [cited by applicant]
US 7792579B2 · Belk et al. · 2010 [cited by applicant]
US 7813798B2 · Bornzin · 2010 [cited by applicant]
US 7844331B2 · Li et al. · 2010 [cited by applicant]
US 7957801B2 · Oosterhoff et al. · 2011 [cited by applicant]
US 8121680B2 · Falkenberg et al. · 2012 [cited by applicant]
US 8170669B2 · Li et al. · 2012 [cited by applicant]
US 8600500B1 · Rosenberg · 2013 [cited by applicant]
US 8706221B2 · Belk et al. · 2014 [cited by applicant]
US 8706224B1 · Bornzin et al. · 2014 [cited by applicant]
US 9468392B2 · Jackson · 2016 [cited by applicant]
US 9468766B2 · Sheldon et al. · 2016 [cited by applicant]
US 9724519B2 · Demmer et al. · 2017 [cited by applicant]
US 10675478B2 · Marshall et al. · 2020 [cited by applicant]
US 11027132B2 · Jackson · 2021 [cited by applicant]
US 20050021095A1 · Rueter et al. · 2005 [cited by applicant]
US 20060217621A1 · Kim · 2006 [cited by examiner]
US 20060247698A1 · Burnes et al. · 2006 [cited by applicant]
US 20070173895A1 · Reichenbach · 2007 [cited by applicant]
US 20070191897A1 · Belk et al. · 2007 [cited by applicant]
US 20080114411A1 · Lian et al. · 2008 [cited by applicant]
US 20090005828A1 · Levine · 2009 [cited by applicant]
US 20090099616A1 · Li et al. · 2009 [cited by applicant]
US 20100228309A1 · Belk et al. · 2010 [cited by applicant]
US 20110319952A1 · Virag et al. · 2011 [cited by applicant]
US 20120191154A1 · Ryu et al. · 2012 [cited by applicant]
US 20120316613A1 · Keefe et al. · 2012 [cited by applicant]
US 20140330327A1 · Thompson-Nauman et al. · 2014 [cited by applicant]
US 20150290467A1 · Ludwig · 2015 [cited by applicant]
US 20150297905A1 · Greenhut et al. · 2015 [cited by applicant]
US 20150306375A1 · Marshall et al. · 2015 [cited by applicant]
US 20150306410A1 · Marshall et al. · 2015 [cited by applicant]
US 20150360041A1 · Stahmann et al. · 2015 [cited by applicant]
US 20160030743A1 · Kaiser · 2016 [cited by applicant]
US 20160051821A1 · Sambelashvili et al. · 2016 [cited by applicant]
US 20160158567A1 · Marshall et al. · 2016 [cited by applicant]
US 20160228026A1 · Jackson et al. · 2016 [cited by applicant]
US 20160235315A1 · Sarkar et al. · 2016 [cited by applicant]
US 20170312534A1 · Cao et al. · 2017 [cited by applicant]
US 20170354827A1 · Zhang et al. · 2017 [cited by applicant]
US 20190083800A1 · Yang et al. · 2019 [cited by applicant]
US 20190134404A1 · Sheldon et al. · 2019 [cited by applicant]
CN 1867376A · 2006 [cited by applicant]
Uldry et al., “Optimization of Antitachycardia Pacing Protocols Applied to Atrial Fibrillation: Insights from a Biophysical Model”, at the Proceedings of the 31st Annual International Conference of the IEEE Embs Minneap… [cited by applicant]
Li Xiaoqing, “Effect of Right Ventricular Electrode Position on Clinical Outcomes and the Occurrence of Ventricular Tachycardia in Patients with Cardiac Resynchronization Pacing Defibrillators”, in the Chinese Journal o… [cited by applicant]
(PCT/US2017/020413) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, Mailed May 22, 2017, 12 pages. [cited by applicant]